Clinical Trials Logo

Rhinitis clinical trials

View clinical trials related to Rhinitis.

Filter by:

NCT ID: NCT00460538 Completed - Clinical trials for Seasonal Allergic Rhinitis

Efficacy and Safety of Lectranal® in Treatment of Seasonal Allergic Rhinitis Symptoms

Start date: April 2007
Phase: Phase 4
Study type: Interventional

The purpose of the study is to determine weather Lectranal is effective in treatment of seasonal allergic rhinitis symptoms.

NCT ID: NCT00458835 Completed - Allergic Rhinitis Clinical Trials

Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)

Start date: April 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the systemic des-ciclesonide exposure of OMNARIS™ (ciclesonide) nasal spray, ciclesonide HFA nasal aerosol, and orally inhaled ciclesonide HFA-metered-dose inhaler (MDI). The administration of the study medication will be as follows: three single doses, separated by a wash-out period. The study will provide further data on the safety and tolerability of ciclesonide.

NCT ID: NCT00456755 Completed - Clinical trials for Perennial Allergic Rhinitis

Herbal Treatment for Perennial Allergic Rhinitis

Start date: March 2004
Phase: Phase 2
Study type: Interventional

Allergic rhinitis(AR) is one of the most common allergic disorders throughout the world.The conventional therapies are effective in alleviating symptoms but the efficacy are limited and not persistent. Furthermonre, the cost and side-effect are known defects. A classical Chinese herbal formula, has been used for AR for centries. Our study purpose is to evaluate the clinical efficacy and safety of this formula verus placebo in perennial allergic rhinitis (PAR). Hypothesis: the classical herbal formula would improve the symptoms of PAR patients and change some immunological parameters in the peripheral blood when comparing with the placebo.

NCT ID: NCT00453063 Completed - Clinical trials for Seasonal Allergic Rhinitis

Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg Once Daily (QD) in the Treatment of Seasonal Allergic Rhinitis (Study P05067)(COMPLETED)

Start date: March 2007
Phase: Phase 3
Study type: Interventional

This study is designed to assess the effectiveness of mometasone furoate nasal spay (MFNS) once daily (QD) compared with placebo in subjects with seasonal allergic rhinitis (SAR) in reducing the total nasal symptom score and the total ocular symptom score.

NCT ID: NCT00449072 Completed - Clinical trials for Rhinitis, Allergic, Perennial

Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)

Start date: March 2007
Phase: Phase 4
Study type: Interventional

The primary objective of the study was to characterize the difference in prepubescent growth velocity in children 3 to 9 years of age with perennial allergic rhinitis (PAR) treated with triamcinolone acetonide (TAA) nasal spray (NASACORT® AQ 110 μg treatment group) or placebo (NASACORT® AQ placebo group) for 12-months. The secondary objectives were to compare the following in prepubertal participants treated with TAA nasal spray versus placebo: - the 24-hour urinary free cortisol levels and the cortisol/creatinine ratio (to measure the Hypothalamic-Pituitary Adrenal [HPA] axis function) - the rate of treatment-emergent-adverse-events (TEAE) - global efficacy rated by the investigator and the participant separately - the rate of use of rescue medication during the study

NCT ID: NCT00446186 Completed - Rhinitis Allergic Clinical Trials

MK0476 Study in Adult Patients With Allergic Rhinitis (0476-378)

Start date: February 2004
Phase: Phase 2
Study type: Interventional

The clinical study evaluates the efficacy and safety of MK0476 in adult patients with allergic rhinitis.

NCT ID: NCT00443495 Completed - Clinical trials for Seasonal Allergic Rhinitis

Phase I/IIa Study on Chitin Microparticles in Subjects Suffering From Allergic Rhinitis

Start date: October 2006
Phase: Phase 1/Phase 2
Study type: Interventional

Chitin microparticles (CMP) has been demonstrated in animal studies that have modelled allergic rhinitis to be effective against a wide range of common respiratory allergens. It is an immuneenhancer. The primary purpose of the study is to demonstrate safety in a first into man study on 24 human volunteers. The secondary objective is to demonstrate efficacy by chosing subjects that demonstrate a response to a nasal allergen challenge using grass pollen. The subjects are being given increasing doses of CMP, supplied as a nasal spray, for 7 days followed by a nasal allergen challenge with Timothy Grass Pollen extract. Over this period nasal symptom scores, eosinophil counts and cytokine measurements will be performed.

NCT ID: NCT00442559 Completed - Asthma Clinical Trials

Montelukast in Mild Asthmatic Children With Allergic Rhinitis (0476-367)

Start date: January 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess real-world effectiveness of montelukast in children (2 to 14 years) with asthma and allergic rhinitis.

NCT ID: NCT00439712 Completed - Clinical trials for Perennial Allergic Rhinitis

Levocetirizine in the Treatment of Nasal Obstruction Due to Perennial Allergic Rhinitis

Start date: February 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to show that in patients suffering from perennial allergic rhinitis levocetirizine 5 mg OD relieves nasal obstruction. Furthermore the study is to investigate how relevant for these patients their nasal obstruction and the effect of levocetirizine on their nasal obstruction are.

NCT ID: NCT00438646 Completed - Asthma Clinical Trials

Oral Bacteria and Allergic Disease in Children

Start date: February 2007
Phase: N/A
Study type: Observational

This study will see if bacteria differ between children who have allergies or asthma and children who do not have allergies or asthma. Previous research suggests that some bacteria may protect against allergies and asthma. This study may provide more information on why some children develop allergies and asthma. Patients at the University of North Carolina-Chapel Hill School of Dentistry who are between 6 and 11 years of age may be eligible for this study. Parents of participating children complete a questionnaire about the child and the child's health. The child provides a saliva sample by chewing a small piece of wax and spitting in a cup. The saliva sample is analyzed in the laboratory for bacteria, yeast and antibodies (substances the body produces to fight germs).